Skip to content
DataLookout
Menu

NCT04678648

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 11 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 15 words
    • Primary completion pushed from Dec 15, 2026 to Mar 16, 2027
    • Study completion pushed from Jan 30, 2027 to Mar 17, 2028
    • Site details revised at 1 of 3 sites
  2. Notable Eligibility criteria expanded, about 33 words
    • Secondary endpoints: 2 to 3
    • Study description expanded, about 11 words
    • Study sites revised (3)
    v11
  3. Notable Primary completion date: Jul 2, 2025 to Dec 15, 2026
    • Study sites: 5 to 3
    • Study completion date: Sep 1, 2025 to Jan 30, 2027
    • Start date: Feb 16, 2021 to Mar 3, 2021
    v10
  4. Notable Primary completion date: Jan 16, 2024 to Jul 2, 2025
    • Study sites: 6 to 5
    • Study completion date: Mar 5, 2024 to Sep 1, 2025
    v9
  5. Minor Site details revised at 1 of 6 sitesv7
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Site details revised at 1 of 6 sitesv6
  2. Minor Site details revised at 1 of 6 sitesv5
  3. Minor Site details revised at 1 of 6 sitesv4
  4. Minor Site details revised at 1 of 6 sitesv3
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 6
    • Start date changed from estimate of Jan 15, 2021 to Feb 16, 2021
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Maximum Tolerated Dose (MTD) for RSC-1255 as monotherapy
Timeframe: Approximately 30 months
Recommended Phase 2 Dose (RP2D) for RSC-1255 as monotherapy
Timeframe: Approximately 12 months

Secondary (3)

Adverse event profile of RSC-1255
Overall Survival (OS)
Disease Progression

Arms and interventions

RSC-1255 TreatmentExperimental

Single Arm Study. All study participants receive RSC-1255.

Drugs: RSC-1255 Dose Escalation, RSC-1255 Dose Expansion

Sites

3 sites in 1 country